These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19209796)

  • 1. [Effectiveness and safety of nadroparin in acute coronary syndrome].
    Lu CL; Ni RY; Yang JG; Hu DY; Guo JX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Aug; 29(4):514-6. PubMed ID: 19209796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy comparison with low and high dose nadroparin for patients with acute coronary syndrome underwent percutaneous coronary intervention].
    Sun CY; Xia HY; Li XQ; Jin LJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Jun; 36(6):493-6. PubMed ID: 19100058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
    Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.
    Bassand JP; Berthe C; Bethencourt A; Bolognese L; Wójcik J;
    Curr Med Res Opin; 2003; 19(2):107-13. PubMed ID: 12740154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes.
    Yan HB; Song L; Liu R; Zhao HJ; Wang SP; Chi YP; Zheng B; Li WZ; Liu C; Zhou P
    Chin Med J (Engl); 2011 Mar; 124(6):879-86. PubMed ID: 21518596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
    Denardo SJ; Davis KE; Tcheng JE
    Am J Cardiol; 2007 Nov; 100(9):1376-82. PubMed ID: 17950793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
    Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
    Alexander JH; Yang H; Becker RC; Kodama K; Goodman S; Dyke CK; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Burton JR; Bovill EG; Kawai C; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2005 Mar; 3(3):439-47. PubMed ID: 15748230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
    J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
    Riezebos RK; Ronner E; Ter Bals E; Slagboom T; Smits PC; ten Berg JM; Kiemeneij F; Amoroso G; Patterson MS; Suttorp MJ; Tijssen JG; Laarman GJ;
    Heart; 2009 May; 95(10):807-12. PubMed ID: 19098058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
    Cohen M; Hoekstra J
    Am J Emerg Med; 2008 Oct; 26(8):932-41. PubMed ID: 18926355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.